Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Coffee as medicine? caffeine shows promise for rare movement disorder

NCT ID NCT04351360

Symptom relief Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small pilot study looked at whether caffeine can ease involuntary movements in people with a rare genetic condition called ADCY5-related dyskinesia. Fifteen participants took caffeine and reported how much their symptoms improved. The goal was to see if at least 40% of people felt significant relief from their movement problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

15 people

The number who actually took part.

Started

May 2020

Finished

May 2021

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with ADCY5-related dyskinesia being actively treated, or who have been previously treated, with caffeine.

Ages

8 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Proven genetic diagnosis of ADCY5-related dyskinesia * Caffeine intake * Non opposition by the patient or the legal representatives if the patient is a minor. No Exclusion Criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADCY5-related dyskinesia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dyskinesia with orofacial involvement dyskinesia with orofacial involvement, autosomal dominant Dyskinesias

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyskinesias

Contacts and locations

Locations

  • Département de Neurologie Groupe Hospitalier Pitié-Salpêtrière

    Paris, 75651 PARIS Cedex 13, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.